Beximco pharma launches generic trikafta

Business Desk:

A group of parents of children living with cystic fibrosis (CF) has launched a community-run buyers’ club to provide global patients access to an affordable generic version of the breakthrough CF drug Trikafta. Developed by Beximco Pharma under the trade name Triko, the medicine will be priced at just $6,375 per child per year-dramatically lower than the $370,000 U.S. list price of the original drug by Vertex Pharmaceuticals.

The announcement was made on last week at the North American Cystic Fibrosis Conference (NACFC) in Seattle, Washington. Triko, containing the triple combination of elexacaftor, tezacaftor, and ivacaftor, is expected to be available from Spring 2026, potentially allowing 58 children to be treated for the cost of treating just one child with the branded version. For adults, the annual price will be $12,750.